Amgen reported success for an injectable formulation of Tepezza (teprotumumab) in a Phase 3 study for thyroid eye disease, setting up an escalation in competition. The company’s move comes as Viridian Therapeutics has also posted Phase 3 results for a rival program. For Tepezza, the injectable data strengthens Amgen’s position in a category where dosing convenience and durability of response can be decisive for adoption. For the field, incoming Phase 3 readouts are likely to intensify price and access negotiations. The next phase will hinge on comparative safety, practical administration, and differentiation versus competitors as regulators review the datasets.